Toni, I received my new 2025 Part D premium with the plan increase going up by 250%, from $25 a month to over $60.

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Novo Nordisk reported one counterfeit pen contained the diabetes medicine insulin. The user was hospitalized ... allows users to verify if a website selling medications has been vetted. You can also ...

At the center of this fight is how the FDA regulates a possible "functional cure" for Type 1 diabetes and determines who gets ...

Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The ...

This list can have an impact on your drug coverage in 2025 and shows why this open enrollment is so important.

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

If you are suffering from insulin resistance, heart disease, or other chronic diseases, there is much you can do to help yourself besides prescription medications. Take steps to reduce chronic ...

Our list of online Wegovy providers includes reputable brands with licensed healthcare providers who can support you on your ...

The owner of one of the three largest pharmacy middlemen in the United States last month filed suit to quash an attempt by the Federal Trade Commission to investigate industry ...